Background：Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily.
RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density.
Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes.
The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.
仕様
サイズ：25ug
Source：Biotinylated Human TNFSF11, His,Avitag, active trimer (RAL-H82Q5) is expressed from human 293 cells (HEK293). It contains AA Gly 64 - Asp 245 (Accession # AAC51762.1) trimer Design.
Molecule：TNFSF11
Synonyms：RANKL,CD254,TRANCE,OPGL,ODF
Species：Human
Tag：His Tag & Avi Tag
Expression Systems：HEK293
Expression Rigeion：Gly 64 - Asp 245
Conjugate：Precision Avi
Accession：AAC51762.1
Molecular Weight：24.1 kDa
Characteristics：This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag). The protein has a calculated MW of 24.1 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level：Less than 1.0 EU per ug by the LAL method.
